Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pacira BioSciences, Inc. - Common Stock (NQ:PCRX)

21.49 +0.22 (+1.03%)
Streaming Delayed Price Updated: 12:37 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pacira BioSciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Pacira BioSciences: Q3 Earnings Insights
Pacira BioSciences (NASDAQ:PCRX) reported its Q3 earnings results on Thursday, November 3, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Pacira BioSciences Reports Third Quarter 2022 Financial Results
From Pacira BioSciences
Via GlobeNewswire
Pacira to Report Third Quarter 2022 Financial Results on Thursday November 3, 2022
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences Reports Preliminary Third Quarter 2022 Revenue of $167.5 Million
-- EXPAREL average daily sales 109% of the prior year for the third quarter and 113% of the prior year for the month of September -- 
From Pacira BioSciences
Via GlobeNewswire
Pacira Touts Positive Data From EXPAREL Study In Toe Correction Surgery
 
Via Benzinga
Pacira Posts Topline Data From Knee Surgery Study With Its Flagship Pain Management Drug
 
Via Benzinga
Pacira Pharmaceuticals Stock Shows Rising Relative Strength
On Friday, Pacira Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 69 to 73. 
Via Investor's Business Daily
Important Biotech Catalysts For September 7, 2022 - End Of The Day Summary
 
Via Benzinga
Pacira BioSciences' Return On Capital Employed Overview
  
Via Benzinga
Pacira BioSciences: Q2 Earnings Insights
  Pacira BioSciences (NASDAQ:PCRX) reported its Q2 earnings results on Wednesday, August 3, 2022. Here's what investors need to know about the announcement. 
Via Benzinga
Pacira to Report Second Quarter 2022 Financial Results on Wednesday August 3, 2022
From Pacira BioSciences
Via GlobeNewswire
Needham Maintains Buy Rating for Pacira BioSciences: Here's What You Need To Know
Needham has decided to maintain its Buy rating of Pacira BioSciences (NASDAQ:PCRX) and lower its price target from $84.00 to $76.00. Shares of Pacira BioSciences are trading up 3.85% over the last 24... 
Via Benzinga
10 Biggest Price Target Changes For Wednesday
Jefferies raised Tapestry, Inc. (NYSE: TPR) price target from $30 to $45. Tapestry shares rose 2.2% to close at $31.60 on Tuesday. 
Via Benzinga
Pacira Pharmaceuticals Stock Shows Improved Relative Price Performance; Still Shy Of Benchmark
On Wednesday, Pacira Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 66 to 75. 
Via Investor's Business Daily
Regeneron Pharmaceutical Stock Sees RS Rating Jump To 82
Looking for the best stocks to buy? Focus on those with rising relative price strength, such as Regeneron Pharmaceutical stock. 
Via Investor's Business Daily
Vertex Pharmaceuticals Receives Composite Rating Upgrade
The IBD SmartSelect Composite Rating for VRTX stock increased from 94 to 96 Tuesday, a sign of strong fundamentals. 
Via Investor's Business Daily
Pacira BioSciences's Return on Invested Capital Overview
Pulled from Benzinga Pro data, Pacira BioSciences (NASDAQ:PCRX) posted Q1 earnings of $6.83 million, an increase from Q4 of 233.1%. Sales dropped to $157.99 million, a 0.76% decrease between quarters. 
Via Benzinga
Gilead Stock Earns Rating Upgrade After Quick Turnaround
A Relative Strength Rating upgrade for Gilead stock shows improving technical performance. Will it continue? 
Via Investor's Business Daily
Pacira BioSciences: Q1 Earnings Insights
Pacira BioSciences (NASDAQ:PCRX) reported its Q1 earnings results on Wednesday, May 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Pacira BioSciences Earnings Conference Call Is Coming Up, Here's What You Need To Know
Pacira BioSciences (NASDAQ:PCRX) will host a conference call at 08:30 AM ET on May 4, 2022, to discuss Q1 2022 earnings results. 
Via Benzinga
Krystal Biotech Stock Sees Healthy Relative Strength Rating Upgrade
On Thursday, Krystal Biotech stock had its Relative Strength (RS) Rating upgraded from to 93, up 88 a day ago. 
Via Investor's Business Daily
28 Biggest Movers From Yesterday
Gainers SailPoint Technologies Holdings, Inc. (NYSE: SAIL) shares jumped 29.16% to close at $64.05 on Monday after private equity firm Thoma Bravo announced plans to acquire... 
Via Benzinga
Supernus Pharmaceuticals Stock Sees Relative Strength Rating Jump To 92
On Thursday, Supernus Pharmaceuticals stock earned an upgrade to its Relative Strength (RS) Rating, from 87 to 92. 
Via Investor's Business Daily
Stocks That Hit 52-Week Highs On Thursday
On Thursday, 75 stocks made new 52-week highs. Interesting Highlights From Today's 52-Week Highs: The largest company by market cap to hit a new 52-week high... 
Via Benzinga
Biohaven Pharma Holdings Stock Joins Elite Club Of Stocks With RS Ratings Over 90
On Wednesday, Biohaven Pharma Holdings stock had its Relative Strength (RS) Rating upgraded to 92 from 86 a day ago. 
Via Investor's Business Daily
Apellis Pharmaceuticals Stock Shows Rising Relative Strength
Apellis Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Monday, rising from 87 to 91. 
Via Investor's Business Daily
Acadia Pharmaceuticals Stock Shows Market Leadership With Jump To 91 RS Rating
Acadia Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, rising from 88 to 91. 
Via Investor's Business Daily
Biocryst Pharmaceuticals Stock Shows Rising Price Performance With Jump To 92 RS Rating
Biotech Biocryst Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded from 88 to 92 Wednesday. 
Via Investor's Business Daily
Horizon Therapeutics Stock Shows Market Leadership; Earns 82 RS Rating
Looking for the best stocks to buy? Horizon Therapeutics stock fits that bill with its Relative Strength Rating upgraded to 82. 
Via Investor's Business Daily
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.